(Oslo, 19 of September 2022) Medistim ASA (OSE: MEDI) is a niche market leader
within ultrasound technology with headquarters in Oslo, Norway. Medistim
develops and commercializes medical equipment for use within cardiac, vascular
and transplant surgery. Today, Medistim announces that the European Society of
Vascular Surgery (ESVS) has revised their Clinical Practice Guidelines on the
management of atherosclerotic carotid and vertebral artery disease by among
others, adding a recommendation of the use of intra-operative completion control
with ultrasound imaging, to reduce risk of peri-operative stroke for patients
undergoing carotid endarterectomy (CEA)1. 

The Guidelines are set to identify luminal thrombus after flow restoration,
diagnose intimal flaps and diagnose residual stenoses during surgery.  

The new recommendation is based on a meta-analysis by Knappich et al. 20212 that
shows that both ultrasound imaging and angiography are associated with a reduced
risk of death and stroke after CEA. 

Professor Eckstein, University Hospital Rechts der Isar, Munich, Germany, states
that "This new guideline recommendation clarifies that intraoperative
morphological control is worthwhile. In my practice, ultrasound imaging for
completion control after CEA has become the standard of care, especially when
surgery is performed under locoregional anesthesia. Intraoperative angiography
is only needed if a cerebral problem is suspected." 

"It is Medistim's goal to develop a strong position for our transit time flow
measurement (TTFM) and high-frequency ultrasound (HFUS) imaging devices within
the Vascular market, including the CEA segment," says Medistim's President and
CEO, Kari E. Krogstad. "The recommendation of ultrasound imaging as an
alternative to the current gold-standard angiography marks another milestone for
Medistim in our efforts to establish our HFUS technology for completion control
in CEA.  In the CIDAC study3, which was part of the Knappich meta-analysis2,
Medistim's MiraQ Vascular device was used, and it demonstrated the benefits of
using HFUS compared to angiography.  So far this year, our vascular product
portfolio revenues have grown more than 40%, and with the support of these
revised Guidelines we are in great position to continue this growth path."

The new Guidelines will be presented at the ESVS conference in Rome the 21st of
September just prior to Medistim's lunch symposium titled "Completion control in
vascular surgery: Lessons learned from the OR", by Prof. Pirkka Vikatmaa,
Helsinki University Hospital.

Reference links: 
1)	https://doi.org/10.1016/j.ejvs.2022.04.011
2)	https://pubmed.ncbi.nlm.nih.gov/34430642/: Ann Transl Med. 2021
Jul